[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 188, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 696080, "exercisedValue": 0, "unexercisedValue": 1659227}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 768400, "exercisedValue": 3280617, "unexercisedValue": 6586792}, {"maxAge": 1, "name": "Ms. Justine E. Koenigsberg", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 29.11, "open": 29.22, "dayLow": 28.28, "dayHigh": 31.185, "regularMarketPreviousClose": 29.11, "regularMarketOpen": 29.22, "regularMarketDayLow": 28.28, "regularMarketDayHigh": 31.185, "payoutRatio": 0.0, "beta": 2.189, "forwardPE": -9.987139, "volume": 264565, "regularMarketVolume": 264565, "averageVolume": 748119, "averageVolume10days": 734540, "averageDailyVolume10Day": 734540, "bid": 30.83, "ask": 31.26, "bidSize": 1, "askSize": 1, "marketCap": 2022546432, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 42.96708, "fiftyDayAverage": 30.0859, "twoHundredDayAverage": 40.475525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1489540736, "profitMargins": 0.0, "floatShares": 42816370, "sharesOutstanding": 65117400, "sharesShort": 7370269, "sharesShortPriorMonth": 7842166, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.113199994, "heldPercentInsiders": 0.02696, "heldPercentInstitutions": 1.10841, "shortRatio": 9.11, "shortPercentOfFloat": 0.143, "impliedSharesOutstanding": 76536304, "bookValue": 12.877, "priceToBook": 2.4120524, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -223858000, "trailingEps": -2.98, "forwardEps": -3.11, "enterpriseToRevenue": 31.644, "enterpriseToEbitda": -5.941, "52WeekChange": -0.24605024, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 31.06, "targetHighPrice": 97.0, "targetLowPrice": 41.0, "targetMeanPrice": 57.66667, "targetMedianPrice": 56.0, "recommendationMean": 1.47368, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 488744000, "totalCashPerShare": 7.526, "ebitda": -250736992, "totalDebt": 87761000, "quickRatio": 7.226, "currentRatio": 7.53, "totalRevenue": 47072000, "debtToEquity": 10.503, "revenuePerShare": 0.627, "returnOnAssets": -0.20652, "returnOnEquity": -0.36382, "grossProfits": -193176000, "freeCashflow": -126831376, "operatingCashflow": -194500992, "revenueGrowth": -0.846, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -10.921689, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Kymera Therapeutics, Inc.", "shortName": "Kymera Therapeutics, Inc.", "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "regularMarketChangePercent": 6.6987247, "regularMarketPrice": 31.06, "corporateActions": [], "regularMarketTime": 1746724720, "fiftyDayAverageChange": 0.9741001, "fiftyDayAverageChangePercent": 0.0323773, "twoHundredDayAverageChange": -9.415525, "twoHundredDayAverageChangePercent": -0.23262268, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "regularMarketChange": 1.9499989, "regularMarketDayRange": "28.28 - 31.185", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 748119, "fiftyTwoWeekLowChange": 11.615, "fiftyTwoWeekLowChangePercent": 0.5973258, "fiftyTwoWeekRange": "19.445 - 53.27", "fiftyTwoWeekHighChange": -22.210001, "fiftyTwoWeekHighChangePercent": -0.4169326, "fiftyTwoWeekChangePercent": -24.605024, "earningsTimestamp": 1746793800, "earningsTimestampStart": 1746793800, "earningsTimestampEnd": 1746793800, "earningsCallTimestampStart": 1746799200, "earningsCallTimestampEnd": 1746799200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.98, "epsForward": -3.11, "epsCurrentYear": -3.73272, "priceEpsCurrentYear": -8.32101, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]